Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nethmi Wickramarathne"'
Autor:
Nirmani Yasara, Nethmi Wickramarathne, Chamila Mettananda, Ishari Silva, Nizri Hameed, Kumari Attanayaka, Rexan Rodrigo, Nirmani Wickramasinghe, Lakshman Perera, Aresha Manamperi, Anuja Premawardhena, Sachith Mettananda
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Hydroxyurea is an antimetabolite drug that induces fetal haemoglobin in sickle cell disease. However, its clinical usefulness in β-thalassaemia is unproven. We conducted a randomised, double-blind, placebo-controlled clinical trial to evalu
Externí odkaz:
https://doaj.org/article/4cc1a47132c94b1ba3eb73830eb877e0
Autor:
Nirmani Yasara, Nethmi Wickramarathne, Chamila Mettananda, Aresha Manamperi, Anuja Premawardhena, Sachith Mettananda
Publikováno v:
BMJ Open, Vol 10, Iss 10 (2020)
Introduction Despite being one of the first diseases to be genetically characterised, β-thalassaemia remains a disorder without a cure in a majority of patients. Most patients with β-thalassaemia receive only supportive treatment and therefore have
Externí odkaz:
https://doaj.org/article/22535198f6a8464ca9d151855e735156
Autor:
Nirmani Yasara, Nethmi Wickramarathne, Chamila Mettananda, Ishari Silva, Nizri Hameed, Kumari Attanayaka, Rexan Rodrigo, Nirmani Wickramasinghe, Lakshman Perera, Aresha Manamperi, Anuja Premawardhena, Sachith Mettananda
Publikováno v:
Scientific reports. 12(1)
Hydroxyurea is an antimetabolite drug that induces fetal haemoglobin in sickle cell disease. However, its clinical usefulness in β-thalassaemia is unproven. We conducted a randomised, double-blind, placebo-controlled clinical trial to evaluate the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51bc27d3f93eaf04933770c88b8dd5a7
https://pubmed.ncbi.nlm.nih.gov/35177777
https://pubmed.ncbi.nlm.nih.gov/35177777
Autor:
Chamila Mettananda, Nirmani Yasara, Anuja Premawardhena, Sachith Mettananda, Nethmi Wickramarathne, A. Manamperi
Publikováno v:
BMJ Open, Vol 10, Iss 10 (2020)
BMJ Open
BMJ Open
IntroductionDespite being one of the first diseases to be genetically characterised, β-thalassaemia remains a disorder without a cure in a majority of patients. Most patients with β-thalassaemia receive only supportive treatment and therefore have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e80180ea8a4158913b1d13a1bab97287
https://bmjopen.bmj.com/content/10/10/e041958.full
https://bmjopen.bmj.com/content/10/10/e041958.full
Autor:
Chamila Mettananda, Sachith Mettananda, Anuja Premawardhena, Nethmi Wickramarathne, Dayananda Bandara, Hashan Pathiraja, Ravindu Peiris, Udaya de Silva
Publikováno v:
Pediatric Blood & Cancer. 66:e27643
Regular blood transfusion therapy still remains the cornerstone in the management of β-thalassemia. Although recommendations are clear for patients with β-thalassemia major, uniform transfusion guidelines are lacking for patients with hemoglobin E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8f457235dc3823af3ce933510e23bce
https://doi.org/10.1002/pbc.27643
https://doi.org/10.1002/pbc.27643